The Health Systems Impact Analysis© (HSIA©)
In the early stages of product, program or policy development there is limited credible information available about the efficacy of a treatment modality. Clinical trial data is usually sealed and not accessible. Pharmacoeconomic data is largely hypothetical, if any exists.
The indication being sought with the regulatory authorities may change, and market entry price of the product is usually decided independent of Canadian corporate interests.
The Health Systems Impact Analysis© (HSIA©) recognizes these hurdles in bringing a product to market independent of the Canadian health care environment. HSIA©'s approach assesses the influence that a product is expected to have on health systems utilization and how it is expected to improve the patient's quality of life.
Computer model building is used to analyze and assess the consequence of introducing a new treatment regiment on the hospital's length of stay (LOS) and use of:
The HSIA© methodology provides a vision of the policy implications of the new medicine six to twelve months before the expected NOC. This vision must be concisely documented in the form of a policy-working document that can be relied on for further briefing purposes.
As new information becomes available, some appreciation should be distilled and articulated about what impact the product will have on the health system as a whole.